A phase 2 study of combination therapy with gemcitabine S-1 and leucovorin in patients with pancreatic cancer
Phase of Trial: Phase II
Latest Information Update: 21 May 2019
At a glance
- Drugs Gemcitabine (Primary) ; Gimeracil/oteracil/tegafur (Primary) ; Folinic acid
- Indications Pancreatic cancer
- Focus Therapeutic Use
- Acronyms GSL-2
- 20 May 2019 Status changed from active, no longer recruiting to completed.
- 31 May 2017 Status changed from recruiting to active, no longer recruiting.
- 16 May 2013 New trial record